骨盆脆性骨折:改善骨质疏松治疗不足的机会
该回顾性队列研究分析了2008至2014年一家大型三级医疗中心及其附属社区医院收治的947例50岁及以上骨盆骨折患者,发现骨质疏松筛查与二级预防严重不足,仅少数患者接受抗骨质疏松治疗,2年内41.0%发生再发脆性骨折。
要点
- 骨盆骨折患者中骨质疏松筛查与治疗率极低,96.0%未接受DXA扫描。
- 治疗初治患者中92.3%从未使用抗骨质疏松药物,2年内41.0%发生再发骨折。
- 骨盆脆性骨折是改善骨质疏松治疗的哨兵事件,应启动筛查与二级预防。
核心结论
- 研究人群中骨盆骨折后骨质疏松筛查和二级预防启动不足,存在改善骨健康的机会。
研究设计与样本
- 回顾性队列研究,纳入2008至2014年一家大型三级医疗中心及其附属社区医院50岁及以上新发骨盆骨折患者947例。
主要发现
- 947例患者中27.1%(257例)骨折前已使用抗骨质疏松药物。
- 治疗初治患者中4%在骨折后1年内开始抗骨质疏松治疗,1.2%(11例)在1年后开始,92.3%(637例)从未处方。
- 2年内41.0%(388例)发生再发脆性骨折,其中12.0%(114例)为髋部骨折,16.4%(155例)为椎体骨折。
- 909例(96.0%)在研究期间从未接受双能X线吸收测定(DXA)扫描。
关键数值与推荐
- 治疗率随时间保持一致。
- 证据等级为预后Level IV。
临床怎么用
- 对50岁及以上骨盆脆性骨折患者应筛查骨质疏松并启动二级预防,包括抗骨质疏松治疗。
局限性
- 研究为回顾性设计,证据等级Level IV。
- 研究机构无既有的二级骨折预防项目。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Osteoporosis is often undiagnosed until patients experience fragility fractures. Pelvic fractures are common but underappreciated sentinel fractures. Screening patients with a pelvic fracture for osteoporosis may provide an opportunity to initiate appropriate treatments such as anti-osteoporosis therapy to prevent additional fractures. METHODS: This retrospective cohort review examined the management of osteoporosis after pelvic fractures at a large tertiary care center without an established secondary fracture prevention program. Data were extracted from electronic medical records of all new patients with a pelvic fracture who were ≥50 years of age from this center and its affiliated community hospitals from 2008 to 2014. Outcome measures included the initiation of anti-osteoporosis therapy before the fracture, within the year following the fracture, >1 year following the fracture, or never and new osteoporotic fractures within 2 years after a pelvic fracture. RESULTS: From 2008 to 2014, 947 patients presented with pelvic fractures. Of these patients, 27.1% (257 patients) were taking anti-osteoporosis medications before the fracture. Four percent of treatment-naïve patients began anti-osteoporosis therapy within 1 year of fracture, with 1.2% (11 patients) starting after 1 year. Of the treatment-naïve patients, 92.3% (637 patients) were never prescribed anti-osteoporosis therapy. Treatment rates were consistent over time. Within 2 years, 41.0% (388 patients) developed fragility fractures at secondary sites: 12.0% (114 patients) experienced a hip fracture, and 16.4% (155 patients) experienced a vertebral fracture. CONCLUSIONS: Osteoporosis screening and initiation of secondary fracture prevention after a pelvic fracture were inadequate in the study population. Of the patients in this study, 909 (96.0%) never underwent a dual x-ray absorptiometry (DXA) scan during the study period. Of the 690 treatment-naïve patients, 637 (92.3%) were never administered anti-osteoporosis medications. Within 2 years, 41.0% of all patients developed additional osteoporotic fractures. This study demonstrates an opportunity to improve bone health by screening for and treating osteoporosis in patients with a pelvic fragility fracture. LEVEL OF EVIDENCE: Prognostic Level IV. See Instructions for Authors for a complete description of levels of evidence.
引用
- Smith CT, Barton DW, Piple AS, et al. Pelvic Fragility Fractures: An Opportunity to Improve the Undertreatment of Osteoporosis. J Bone Joint Surg Am. 2021. PMID: 33269895. doi:10.2106/JBJS.20.00738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。